# OnCo record cancer-of-unknown-primary (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cancer-of-unknown-primary/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cancer-of-unknown-primary" ;
  schema:name "Cancer of unknown primary (CUP)"@en ;
  schema:alternateName "CUP"@en, "Occult primary"@en ;
  schema:description "Cancer found already spread, where doctors cannot find where it started. Genomic profiling finds a drug target in about a third of cases and tumour-agnostic approvals apply directly; the rest still rely on general-purpose chemotherapy, which is what those tests are changing."@en ;
  schema:url <https://onco.cc/cancers/cancer-of-unknown-primary/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1024546> ;
  schema:citation <https://doi.org/10.1016/j.annonc.2022.11.013>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1451>, <https://www.cupfoundjo.org/> ;
  onco:tag "gap-fill", "site-agnostic" ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/foundation-medicine/>, <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/ihc/> ;
  onco:people <https://onco.cc/people/jim-valvano/> ;
  onco:pipeline <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/> .